| Drug Name |
Rivastigmine |
| Drug ID |
BADD_D01955 |
| Description |
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. |
| Indications and Usage |
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type. |
| Marketing Status |
approved; investigational |
| ATC Code |
N06DA03 |
| DrugBank ID |
DB00989
|
| KEGG ID |
D03822
|
| MeSH ID |
D000068836
|
| PubChem ID |
77991
|
| TTD Drug ID |
D0WY5Q
|
| NDC Product Code |
16714-117; 70710-1198; 72855-101; 0781-7304; 65372-1153; 82245-0107; 51956-0001; 51956-0002; 51991-898; 65162-826; 72855-102; 49706-1825; 0078-0503; 63629-2065; 65162-749; 65162-825; 0378-9072; 0781-7309; 12651-118; 64552-4021; 65015-819; 0078-0501; 63629-8846; 0378-9071; 70710-1196; 16714-115; 63629-2066; 50379-0014; 65862-982; 72855-100; 51956-0003; 51991-897; 51991-899; 0781-7313; 63629-2064; 0378-9070; 0078-0502; 16714-116; 63629-8807; 70710-1197 |
| UNII |
PKI06M3IW0
|
| Synonyms |
Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713 |
